Pentagon Implements Mandatory Testosterone Screening for Male Service Members Over 30

WASHINGTON — The Pentagon has issued formal clinical guidance for mandatory testosterone testing targeting male service members aged 30 and older. The new policy, released Thursday, excludes women from the initial screening requirements and has drawn scrutiny from medical experts regarding the necessity and effectiveness of such a program.

Defense Secretary Pete Hegseth announced the initiative in July, stating that screening for “testosterone deficiency” was essential to ensure troops could perform at their “absolute best.” The policy comes as interest in hormone therapy has surged among men, driven by health influencers who often promote testosterone as a remedy for low energy, muscle loss, and aging—claims that many scientists argue lack robust evidentiary support.

The directive specifies that mandatory screening applies to male personnel, marking a shift from Hegseth’s original July memo, which had called for testing all troops regardless of gender. While the current guidance limits the mandate to men, it notes that female clinical practice guidelines are under review and will be published upon approval. It remains unclear whether female service members will be evaluated for estrogen-based therapies during perimenopause.

Pentagon spokesperson Sean Parnell stated that the goal is to “invest in the health of its warfighters, strengthen their performance, and maximize force readiness” by proactively identifying suboptimal hormone levels. However, major medical organizations generally advise against routine asymptomatic screening. Standard guidelines typically recommend treatment only for men exhibiting symptoms such as depressed mood or low libido who have confirmed low hormone levels through repeated blood tests.

The Pentagon’s new guidelines acknowledge scientific limitations on the hormone’s benefits, explicitly stating that evidence does not support testosterone use for improving energy, vitality, physical function, or cognition. Instead, the document highlights proven benefits for sexual function and bone density. The policy does not compel service members to undergo replacement therapy if they test positive, but it does warn of established side effects, including potential reductions in sperm count.

Consequently, military physicians are instructed against prescribing testosterone therapy to individuals wishing to father children in the near future. Practical challenges also persist for deployed troops; the memo notes that testosterone is a controlled substance requiring specific storage conditions and accountability measures. These logistical hurdles contrast with Hegseth’s earlier assertions that the therapy was vital for maintaining maximum psychological readiness in modern combat environments.